BBC\u2019nin haberine g\u00f6re, \u0130ngiltere\u2019de \u00e7\u0131\u011f\u0131r a\u00e7an yeni bir tedavi, T h\u00fccreli akut lenfoblastik l\u00f6semi (T-ALL) tedavisinde umut oldu. Bu tedavinin uyguland\u0131\u011f\u0131 T-ALL hastas\u0131 11 ki\u015fi, kan kanserini atlatarak sa\u011fl\u0131\u011f\u0131na kavu\u015ftu. Tedavi, beyaz kan h\u00fccrelerindeki DNA\u2019n\u0131n hassas \u015fekilde d\u00fczenlenerek kanserle sava\u015fan \u201ccanl\u0131 bir ilaca\u201d d\u00f6n\u00fc\u015ft\u00fcr\u00fclmesini i\u00e7eriyor. Bu tedavinin ilk uyguland\u0131\u011f\u0131 ki\u015fi olan ve \u015fimdi kansersiz bir hayat s\u00fcrd\u00fcren 16 ya\u015f\u0131ndaki Alyssa Tapley\u2019e 2021\u2019de T h\u00fccreli akut lenfoblastik l\u00f6semi te\u015fhisi konmu\u015ftu.<\/p>\n
\u00d6l\u00fcmden d\u00f6nd\u00fcler<\/strong><\/p>\n Alyssa\u2019ya uygulanan kemoterapiden ve kemik ili\u011fi naklinden sonu\u00e7 al\u0131namam\u0131\u015ft\u0131. \u00d6lece\u011fini d\u00fc\u015f\u00fcnen gen\u00e7 k\u0131z, 2022\u2019de uygulanan \u00e7\u0131\u011f\u0131r a\u00e7an DNA tedavisiyle l\u00f6semiden kurtuldu. T\u0131pk\u0131 Alyssa gibi bilinen tedavilere cevap vermeyen 10 hasta daha yeni DNA tedavisiyle iyile\u015fti. Uzmanlar, \u201cGenetik bilimindeki ilerlemeler daha \u00f6nce olanaks\u0131z olan bir tedaviyi m\u00fcmk\u00fcn k\u0131ld\u0131. \u0130lk kez \u00fc\u00e7 y\u0131l \u00f6nce uygulanan DNA tedavisi, eski ba\u011f\u0131\u015f\u0131kl\u0131k sistemini yok edip yeni bir ba\u011f\u0131\u015f\u0131kl\u0131k sistemi geli\u015ftirerek l\u00f6semiyle sava\u015f\u0131yor\u201d dedi.<\/p>\n \u2018CAR-T uygulan\u0131r hale gelmi\u015ftir\u2019<\/strong><\/p>\n Prof. Dr. Burhan Turgut (Medical Park Bah\u00e7elievler Hastanesi): \u201cBu \u00e7al\u0131\u015fma \u00f6nemli bir tedaviyi ortaya koymaktad\u0131r. T h\u00fccreli akut \u00a0\u00a0 lenfoblastik l\u00f6semide art\u0131k CAR-T h\u00fccre tedavisi uygulan\u0131r hale gelmi\u015ftir. CAR-T h\u00fccre tedavisi, kansere kar\u015f\u0131 savunmada en \u00f6nemli h\u00fccreler olan T lenfositlerin genetik m\u00fchendislikle de\u011fi\u015ftirilerek kanser h\u00fccrelerini yok etmelerine dayanmaktad\u0131r. Bu tedavi \u00f6zellikle akut lenfoblastik l\u00f6semi, B h\u00fccreli lenfomalar ve multipl myelom gibi hematolojik kanserlerde son y\u0131llarda kullan\u0131lmaktad\u0131r.\u201d -D\u0130DEM SEYMEN Haber Merkezi<\/strong><\/p>\n \u2018T\u00fcrkiye\u2019de de\u00a0 s\u0131n\u0131rl\u0131 uygulamalar var\u2019<\/strong><\/p>\n \u00a0T\u00fcrkiye\u2019de de bu konuda preklinik \u00e7al\u0131\u015fmalar ve klinik \u00e7al\u0131\u015fma baz\u0131nda s\u0131n\u0131rl\u0131 uygulamalar oldu\u011funu belirten Prof. Dr. Burhan Turgut, \u015funlar\u0131 s\u00f6yledi: \u201cBu uygulamayla l\u00f6semi tamamen ortadan kald\u0131r\u0131labiliyor. Ancak bu tedavi sonunda hastan\u0131n v\u00fccudundaki sa\u011fl\u0131kl\u0131 T lenfositler de yok edildi\u011fi i\u00e7in k\u00f6k h\u00fccre nakliyle hastaya yeni bir imm\u00fcn sistem (ba\u011f\u0131\u015f\u0131kl\u0131k sistemi) sa\u011flanmas\u0131 gerekiyor. \u00c7al\u0131\u015fmada baz\u0131 hastalar\u0131n hayat\u0131 kurtar\u0131lm\u0131\u015f olmakla birlikte yan etkilerin kontrol\u00fcyle ilgili \u00e7al\u0131\u015fmalar\u0131n devam\u0131 gerekir. Bu ve benzeri ba\u011f\u0131\u015f\u0131kl\u0131k sistemi h\u00fccrelerinin genetik m\u00fchendislikle de\u011fi\u015ftirilip kansere kar\u015f\u0131 kullan\u0131m\u0131 her g\u00fcn yeni bir ivme kazanmaktad\u0131r.\u201d<\/p>\n\n <\/p>\n Kaynak :\u00a0http:\/\/www.milliyet.com.tr\/gundem\/losemide-buyuk-umut-7499033<\/span><\/p>\n","protected":false},"excerpt":{"rendered":" \u0130ngiltere\u2019de a\u011f\u0131r l\u00f6semi hastas\u0131 11 ki\u015fi, yeni bir tedaviyle hastal\u0131\u011f\u0131 atlatt\u0131. Tedavi, beyaz kan h\u00fccrelerindeki DNA\u2019n\u0131n d\u00fczenlenerek kanserle sava\u015fan bir ilaca d\u00f6n\u00fc\u015ft\u00fcr\u00fclmesini i\u00e7eriyor.<\/p>\n","protected":false},"author":1,"featured_media":152197,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[5438,3271,10162,357,5204],"class_list":["post-152196","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-guncel","tag-hucre","tag-kan","tag-losemi","tag-tedavi","tag-tedavisi"],"_links":{"self":[{"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/posts\/152196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/comments?post=152196"}],"version-history":[{"count":1,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/posts\/152196\/revisions"}],"predecessor-version":[{"id":152198,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/posts\/152196\/revisions\/152198"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/media\/152197"}],"wp:attachment":[{"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/media?parent=152196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/categories?post=152196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/tags?post=152196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}